Nadar Sunil K, Shaikh Mohammad Mujtaba
Department of Medicine, Sultan Qaboos University Hospital Muscat, Oman.
Card Fail Rev. 2019 Feb;5(1):50-56. doi: 10.15420/cfr.2018.27.2.
Heart failure is a clinical condition with complex pathophysiology that involves many different processes. Diagnosis is often difficult in patients presenting for the first time with breathlessness. Many biomarkers have been identified that are elevated in heart failure and their role in assessing prognosis has also been investigated. However, at present the natriuretic peptides appear to be the gold standard biomarker against which the other biomarkers are compared. In this review we will examine the evidence behind the other biomarkers for use in heart failure patients and the current guidelines for their use.
心力衰竭是一种具有复杂病理生理学的临床病症，涉及许多不同的过程。对于首次出现呼吸困难的患者，诊断往往很困难。已经确定了许多在心力衰竭中升高的生物标志物，并且它们在评估预后中的作用也已得到研究。然而，目前利钠肽似乎是用于与其他生物标志物进行比较的金标准生物标志物。在本综述中，我们将研究用于心力衰竭患者的其他生物标志物背后的证据以及它们的当前使用指南。
